A detailed history of Mitsubishi Ufj Kokusai Asset Management Co., Ltd. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Mitsubishi Ufj Kokusai Asset Management Co., Ltd. holds 3,200,215 shares of BMY stock, worth $186 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares
3,200,215
Previous 2,901,220 10.31%
Holding current value
$186 Million
Previous $120 Million 37.45%
% of portfolio
0.18%
Previous 0.15%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$39.66 - $51.75 $11.9 Million - $15.5 Million
298,995 Added 10.31%
3,200,215 $166 Million
Q2 2024

Aug 12, 2024

BUY
$40.25 - $52.99 $13 Million - $17.2 Million
324,042 Added 12.57%
2,901,220 $120 Million
Q1 2024

May 09, 2024

BUY
$47.98 - $54.4 $24.5 Million - $27.7 Million
510,023 Added 24.67%
2,577,178 $140 Million
Q4 2023

Feb 08, 2024

BUY
$48.48 - $57.85 $4.88 Million - $5.82 Million
100,689 Added 5.12%
2,067,155 $106 Million
Q3 2023

Nov 07, 2023

BUY
$57.89 - $64.73 $8.67 Million - $9.7 Million
149,777 Added 8.24%
1,966,466 $114 Million
Q2 2023

Aug 09, 2023

BUY
$63.71 - $70.74 $7.41 Million - $8.23 Million
116,285 Added 6.84%
1,816,689 $116 Million
Q1 2023

May 08, 2023

BUY
$65.71 - $74.53 $11 Million - $12.4 Million
167,037 Added 10.89%
1,700,404 $118 Million
Q4 2022

Feb 07, 2023

BUY
$68.48 - $81.09 $11.9 Million - $14.1 Million
173,673 Added 12.77%
1,533,367 $110 Million
Q3 2022

Nov 01, 2022

BUY
$0.13 - $76.84 $15,332 - $9.06 Million
117,939 Added 9.5%
1,359,694 $96.7 Million
Q2 2022

Aug 04, 2022

BUY
$72.62 - $79.98 $5.91 Million - $6.5 Million
81,318 Added 7.01%
1,241,755 $95.6 Million
Q1 2022

May 09, 2022

BUY
$61.48 - $73.72 $5.49 Million - $6.58 Million
89,243 Added 8.33%
1,160,437 $84.7 Million
Q4 2021

Feb 07, 2022

BUY
$53.63 - $62.52 $7.8 Million - $9.1 Million
145,476 Added 15.71%
1,071,194 $66.3 Million
Q3 2021

Nov 04, 2021

BUY
$59.17 - $69.31 $5.1 Million - $5.97 Million
86,195 Added 10.27%
925,718 $54.8 Million
Q2 2021

Aug 06, 2021

BUY
$61.91 - $67.42 $6.51 Million - $7.09 Million
105,089 Added 14.31%
839,523 $56.1 Million
Q1 2021

May 06, 2021

BUY
$59.34 - $66.74 $4.9 Million - $5.51 Million
82,553 Added 12.66%
734,434 $46.4 Million
Q4 2020

Feb 09, 2021

BUY
$57.74 - $65.43 $2.03 Million - $2.3 Million
35,088 Added 5.69%
651,881 $40.4 Million
Q3 2020

Nov 10, 2020

BUY
$57.43 - $63.64 $5.44 Million - $6.03 Million
94,718 Added 18.14%
616,793 $37.2 Million
Q2 2020

Aug 06, 2020

BUY
$54.82 - $64.09 $2.28 Million - $2.67 Million
41,647 Added 8.67%
522,075 $30.7 Million
Q1 2020

May 11, 2020

SELL
$46.4 - $67.43 $366,606 - $532,764
-7,901 Reduced 1.62%
480,428 $26.8 Million
Q4 2019

Feb 05, 2020

BUY
$49.21 - $64.19 $9.24 Million - $12.1 Million
187,753 Added 62.46%
488,329 $30.7 Million
Q3 2019

Nov 12, 2019

BUY
$42.77 - $50.71 $489,246 - $580,071
11,439 Added 3.96%
300,576 $15.2 Million
Q2 2019

Aug 08, 2019

BUY
$44.62 - $49.34 $3.1 Million - $3.43 Million
69,497 Added 31.64%
289,137 $13.1 Million
Q1 2019

Apr 26, 2019

BUY
$45.12 - $53.8 $648,825 - $773,644
14,380 Added 7.01%
219,640 $10.5 Million
Q4 2018

Feb 08, 2019

SELL
$48.76 - $63.23 $1.48 Million - $1.92 Million
-30,375 Reduced 12.89%
205,260 $9.26 Million
Q3 2018

Nov 13, 2018

SELL
$55.19 - $62.25 $249,513 - $281,432
-4,521 Reduced 1.88%
235,635 $14.6 Million
Q2 2018

Aug 09, 2018

BUY
$50.53 - $62.98 $577,153 - $719,357
11,422 Added 4.99%
240,156 $13.3 Million
Q1 2018

May 02, 2018

SELL
$59.92 - $68.98 $1.28 Million - $1.47 Million
-21,344 Reduced 8.53%
228,734 $14.5 Million
Q4 2017

Feb 06, 2018

BUY
$59.94 - $65.35 $211,408 - $230,489
3,527 Added 1.43%
250,078 $15.3 Million
Q3 2017

Nov 01, 2017

BUY
$55.23 - $63.74 $13.6 Million - $15.7 Million
246,551
246,551 $15.7 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Portfolio

Follow Mitsubishi Ufj Kokusai Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.